Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination
Authors Inoue K, Piao H, Iwasa M, Ishida K, Tomita G
Received 29 November 2019
Accepted for publication 17 March 2020
Published 4 May 2020 Volume 2020:14 Pages 1207—1214
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Kenji Inoue,1 Hua Piao,1 Mayumi Iwasa,1 Kyoko Ishida,2 Goji Tomita2
1Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan
Correspondence: Kenji Inoue
Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan
Tel +81 3 3295 0911
Fax +81 3 3295 0917
Purpose: To investigate the short-term intraocular pressure-lowering efficacy and safety of switching from a fixed combination of latanoprost/timolol to a fixed combination of latanoprost/carteolol.
Patients and Methods: The subjects were 30 eyes of 30 adult patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who were using a latanoprost-/timolol-fixed combination with insufficient intraocular pressure-lowering efficacy or adverse reactions. The subjects were switched from once-daily latanoprost/timolol to once-daily latanoprost/carteolol with no washout interval. Intraocular pressure, tear film break-up time, corneal epithelial defects, conjunctival hyperemia, blood pressure, and pulse rate were measured and compared before and 1 and 3 months after switching. Patients were monitored for adverse reactions at each visit, and dropouts were recorded.
Results: The mean intraocular pressure at 1 month (15.9± 3.1 mmHg) and 3 months (16.3± 3.8 mmHg) was not significantly different from that at baseline (16.1± 3.1 mmHg). The tear film break-up time and corneal epithelial defects were significantly improved after switching (p< 0.01 and p< 0.0001, respectively). There was a significant decrease in systolic blood pressure after 1 month and diastolic pressure after 3 months (p< 0.05). There was no significant change in pulse rate during the study. Adverse reactions (blurred vision, blepharitis, and conjunctival hyperemia) occurred in 3 patients (10.0%). Four patients (13.3%) discontinued treatment during the 3-month study period.
Conclusion: A switch from a fixed combination of latanoprost/timolol to that of latanoprost/carteolol can maintain intraocular pressure and adherence with once-daily administration while improving tear film break-up time and corneal epithelial defects.
Keywords: adverse reactions, eye drops, glaucoma, intraocular pressure
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]